---
title: "Nucala (mepolizumab) in severe eosinophilic asthma: Real-world evidence questions"
description: "Real-world evidence questions on Nucala (mepolizumab) in severe eosinophilic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Did Nucala reduce asthma exacerbations in real-world use (REALITI-A)? How many patients stopped Nucala in the REALITI-A real-world study? Did Nucala reduce asthma hospitalizations in the REALITI-A real-world study? How many OCS-dependent REALITI-A patients stopped oral steroids on Nucala? 4 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/real-world-evidence"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Nucala (mepolizumab) in severe eosinophilic asthma: Real-world evidence questions

Manufacturer: GlaxoSmithKline  
Prescribing information: [Nucala](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF)

Questions that apply to every indication of Nucala are on [Nucala (mepolizumab), all indications](https://www.evicenter.com/medical-information/nucala).

## Real-world evidence

<a id="nucala-realiti-a-exacerbations"></a>

### Did Nucala reduce asthma exacerbations in real-world use (REALITI-A)?

> “Description<sup>6,7</sup>: 2-year, global, single-arm, prospective, cohort study assessing the real-world effectiveness and safety of NUCALA 100 mg every 4 weeks in 822 adult patients with severe eosinophilic asthma (SEA) who met the eligibility requirements to initiate NUCALA. Data were collected prospectively at usual asthma healthcare visits. A 1-year period of relevant medical data was required prior to enrollment and was collected retrospectively at enrollment from medical records and patient recall for the previous year. Baseline visit was first administration of NUCALA.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=2%2Dyear%2C%20global%2C%20single%2Darm%2C%20prospective%2C%20cohort,was%20first%20administration%20of%20NUCALA.)

On the page, select: REALITI-A: Study description, primary/secondary objectives, safety, and baseline characteristics

> “Primary objective: Exacerbation† rate with NUCALA (1-year post-exposure) vs pre-NUCALA (1-year pre-exposure): 1.24/year vs 4.29/year, 71% reduction; rate ratio 0.29 (95% CI: 0.26, 0.32). Results are descriptive.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Primary%20objective%3A%20Exacerbation%E2%80%A0%20rate%20with,0.26%2C%200.32%29.%20Results%20are%20descriptive.)

On the page, select: REALITI-A: Study description, primary/secondary objectives, safety, and baseline characteristics

> “Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Real%2Dworld%20studies%20are%20designed%20to,collection%20vs%20randomized%20controlled%20trials.)

On the page, select: REALITI-A: Study description, primary/secondary objectives, safety, and baseline characteristics

<a id="nucala-realiti-a-discontinuation"></a>

### How many patients stopped Nucala in the REALITI-A real-world study?

> “Discontinuations at 2 years (N=822): 27% discontinued NUCALA treatment (2% due to an AE; 9%, lack of reported efficacy; 15%, other).
>
> AEs in safety population (N=823): Any drug-related AE, 11%; serious AE, <1%. Most common AE reported was headache, 4%.”

Source: [NUCALA: SEA Study Designs, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/study-designs/#:~:text=Discontinuations%20at%202%20years%20%28N%3D822%29%3A,AE%20reported%20was%20headache%2C%204%25.)

On the page, select: REALITI-A: Study description, primary/secondary objectives, safety, and baseline characteristics

<a id="nucala-realiti-a-hospitalizations"></a>

### Did Nucala reduce asthma hospitalizations in the REALITI-A real-world study?

> “Real-world study (REALITI-A): 69% reduction in exacerbations requiring hospitalization with NUCALA (1-year post-exposure, N=820) vs pre-NUCALA (1-year pre-exposure, N=821), 0.14 vs 0.45, rate ratio: 0.31 (95% CI: 0.24, 0.39), secondary objective. 91% had zero exacerbations requiring hospitalization with NUCALA vs 76% pre-NUCALA.<sup>2</sup> All results are descriptive.”

Source: [NUCALA: SEA Comorbidity Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/comorbidity-data/#:~:text=Real%2Dworld%20study%20%28REALITI%2DA%29%3A%2069%25%20reduction,All%20results%20are%20descriptive.)

<a id="nucala-realiti-a-oral-steroids"></a>

### How many OCS-dependent REALITI-A patients stopped oral steroids on Nucala?

> “COMPLETELY ELIMINATED
> maintenance OCS use* (95/168)
> with NUCALA at 2 years (Weeks 101-104)”

Source: [NUCALA: SEA OCS Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/ocs-reduction/#:~:text=maintenance%20OCS%20use%2A%20%2895%2F168%29,at%202%20years%20%28Weeks%20101%2D104%29)

> “Secondary objective. Results are descriptive.”

Source: [NUCALA: SEA OCS Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/ocs-reduction/#:~:text=Secondary%20objective.%20Results%20are%20descriptive.)

> “Real-world study limitations: 2-year, single-arm, prospective, observational cohort study. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: no comparator arm; differences in patient populations and data collection vs randomized controlled trials.<sup>2</sup>”

Source: [NUCALA: SEA OCS Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/ocs-reduction/#:~:text=objective.%20Results%20are%20descriptive.-,Real%2Dworld%20study%20limitations%3A%202%2Dyear%2C%20single%2Darm%2C%20prospective%2C%20observational%20cohort%20study.%20Real%2Dworld,collection%20vs%20randomized%20controlled%20trials.2)

> “*Baseline maintenance OCS dose (prednisone equivalent mg/day) defined as average daily dose in the 28 days prior to treatment index. Dose assessments based on data captured from medical records or patient recall without documentation of asthma control.<sup>2</sup>”

Source: [NUCALA: SEA OCS Data, captured 2026-11-14](https://nucalahcp.com/severe-eosinophilic-asthma/efficacy-safety/ocs-reduction/#:~:text=%2ABaseline%20maintenance%20OCS%20dose%20%28prednisone,recall%20without%20documentation%20of%20asthma)

Note: The page shows the percentage in a graphic that the capture did not record as text; the quoted count is 95 of 168 patients.

## Related pages
- [Medical information: Nucala (mepolizumab): Severe eosinophilic asthma](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma)
- [Indication](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/nucala--severe-eosinophilic-asthma/access-and-coverage)
